share_log

Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum維持對Champions Oncology的買入評級,將目標價上調至8美元
Benzinga ·  2024/12/13 00:23  · 評級/大行評級

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $6 to $8.

Craig-Hallum的分析師Matt Hewitt維持Champions Oncology(納斯達克:CSBR)的買入評級,並將價格目標從$6提高至$8。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論